ReviewSurgical neurology international2026
Assessing the efficacy and safety of transcranial magnetic stimulation and vagus nerve stimulation for drug-resistant epilepsy: A systematic review.
Review in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-resistant epilepsy (DRE), characterized by inadequate seizure control despite adequate trials of multiple antiepileptic medications, affects a substantial proportion of the global epilepsy population. Recent advances in neuromodulation techniques have demonstrated promise as adjunctive therapeutic approaches for managing treatment-resistant epilepsy. Transcranial magnetic stimulation (TMS) and vagus nerve stimulation (VNS) represent emerging interventions for patients who fail conventional pharmacological management. Methods: A comprehensive search was performed for multiple databases such as PubMed, Cochrane Library, and Google Scholar. Search was done for studies from 1995 to 2024, which will meet our inclusion criteria and exclusion criteria. We selected 36 studies that include randomized controlled trials, observational studies, and retrospective analyses. Our primary outcome is seizure recurrence, and the secondary outcomes are adverse events. Our systematic review is registered in PROSPERO, and its ID is CRD42025629381. Results: Approximately 47% of patients treated with either TMS or VNS were found to have a mean seizure reduction of over 50%, which also contributed to the results of our data interpretation. Even in several institutional studies, it was additionally found that more than 60% of patients showed significant improvements in seizure control. Conclusion: Evidence reported that both TMS and VNS greatly improve seizure control in patients with drug-resistant epilepsy, potentially enhancing quality of life and reducing seizure frequency. A large amount of our findings support the integration of neuromodulation techniques into future treatment regimens for drug-resistant epilepsy, which might be accompanied by calls for future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.